Free Trial
→ Bank of America Says Gold Could Hit $4,000. Here How to Get Paid (From Investors Alley) (Ad) Free AYTU Stock Alerts

Aytu BioPharma (AYTU) SEC Filings & 10K Form

Aytu BioPharma logo
$2.32 +0.15 (+6.91%)
Closing price 04:00 PM Eastern
Extended Trading
$2.36 +0.04 (+1.51%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Aytu BioPharma SEC Filings

Export to Excel
DateFilerForm TypeView
06/26/2025
4:18 PM		Aytu BioPharma (Subject)
Philotimo Fund, LP (Filed by)
Form SCHEDULE 13G/A
06/26/2025
4:31 PM		Aytu BioPharma (Subject)
Philotimo Fund, LP (Filed by)
Form SCHEDULE 13G/A
06/26/2025
4:36 PM		Aytu BioPharma (Subject)
Philotimo Fund, LP (Filed by)
Form SCHEDULE 13G
06/26/2025
4:01 PM		Aytu BioPharma (Subject)
Philotimo Fund, LP (Filed by)
Form SCHEDULE 13G
06/23/2025
7:00 AM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2025
5:05 AM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2025
1:09 PM		Aytu BioPharma (Subject)
LYTTON LAURENCE W (Filed by)
Form SCHEDULE 13G
06/10/2025
2:04 PM		Aytu BioPharma (Issuer)
Disbrow Joshua R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
2:06 PM		Aytu BioPharma (Issuer)
Disbrow Jarrett (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025
5:02 AM		Aytu BioPharma (Filer)
Form 424B4
06/05/2025
11:15 PM		Aytu BioPharma (Filer)
Form EFFECT
06/06/2025
5:01 AM		Aytu BioPharma (Filer)
Form S-1MEF
05/21/2025
3:20 PM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2025
3:34 PM		Aytu BioPharma (Issuer)
PYSZCZYMUKA GREG (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
6:22 PM		Aytu BioPharma (Issuer)
Selhorn Ryan J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
12:35 PM		Aytu BioPharma (Issuer)
Disbrow Joshua R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2024
8:30 PM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
4:36 PM		Aytu BioPharma (Subject)
Stonepine Capital Management, LLC (Filed by)
Form SC 13G/A
11/13/2024
4:20 PM		Aytu BioPharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
3:05 PM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
3:08 PM		Aytu BioPharma (Issuer)
Selhorn Ryan J (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/08/2024
7:44 PM		Aytu BioPharma (Issuer)
DOCKERY CARL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
7:27 PM		Aytu BioPharma (Issuer)
JAIN ABHINAV (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
7:34 PM		Aytu BioPharma (Issuer)
Donofrio John Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
6:49 PM		Aytu BioPharma (Issuer)
Disbrow Jarrett (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
6:55 PM		Aytu BioPharma (Issuer)
Disbrow Joshua R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
6:32 PM		Aytu BioPharma (Issuer)
LIU VIVIAN H (Reporting)
Form 4/A
11/08/2024
6:37 PM		Aytu BioPharma (Issuer)
LIU VIVIAN H (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
6:23 PM		Aytu BioPharma (Issuer)
PYSZCZYMUKA GREG (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
11:15 PM		Aytu BioPharma (Filer)
Form EFFECT
10/11/2024
4:01 PM		Aytu BioPharma (Filer)
Form S-3/A
10/02/2024
4:18 PM		Aytu BioPharma (Issuer)
PYSZCZYMUKA GREG (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2024
7:00 AM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2024
3:29 PM		Aytu BioPharma (Filer)
Form S-3
Registration statement under Securities Act of 1933  
09/26/2024
3:32 PM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2024
7:00 AM		Aytu BioPharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:AYTU) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners
Bank of America Says Gold Could Hit $4,000. Here How to Get Paid
“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...
Investors Alley | Sponsored
Revolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial Underway
Tiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!
Interactive Offers | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
[ATTENTION] This Crypto Rocket Is About Launch…
Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...
Crypto Swap Profits | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored